Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle

Journal of Nanoparticle Research

Volumn 16, Issue 1, 2014, Pages

  Tang, Hailin ^a   Xie, Xinhua ^a   Guo, Jiaoli ^b   Wei, Weidong ^a   Wu, Minqing ^a   Liu, Peng ^a   Kong, Yanan ^a   Yang, Lu ^a   Hung, Mien Chie ^c   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Fenggang People's Hospital   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BikDD; Delivery system; Nanomedicine; Nanoparticle; XM001

Indexed keywords

BIKDD; DELIVERY SYSTEMS; GENE DELIVERY SYSTEMS; HUMAN BREAST CANCER CELLS; PRO-APOPTOTIC GENES; SELF ASSEMBLED NANOPARTICLES; TRANSFECTION AGENTS; XM001;

CELL CULTURE; DRUG THERAPY; GENE TRANSFER; GENES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

TUMORS;

DNA; NANOPARTICLE; SELF ASSEMBLED NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL; BREAST TUMOR; CANCER CELL; GENE; GENE DELIVERY SYSTEM; GENE TARGETING; LIFESPAN; MUTANT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SAFETY; TUMOR CELL LINE;

EID: 84890844691     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-2213-1     Document Type: Article

References (17)

1. Braeckmans K, Buyens K, Naeye B, Vercauteren D, Deschout H, Raemdonck K, Remaut K, Sanders NN, Demeester J, De Smedt SC (2010) Advanced fluorescence microscopy methods illuminate the transfection pathway of nucleic acid nanoparticles. J Control Release 148:69-74
2. Burstein HJ, Winer EP (2009) Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrere F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougneres P, Von Kalle C, Fischer A, Cavazzana-Calvo MAubourg P (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823
4. Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV, Ponnazhagan P (2008) Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 16:871-878 (Pubitemid 351587096)
5. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC (2006) Mutant Bik expression mediated by the enhanced minimal topoisomerase II alpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 13:706-719 (Pubitemid 44264474)
6. Ellisen LW (2011) PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 19:165-167
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
8. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC (2011) BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20:341-356
9. Lee M (2009) Hypoxia targeting gene expression for breast cancer gene therapy. Adv Drug Deliv Rev 61:842-849
10. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC (2003) Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 63:7630-7633 (Pubitemid 37466686)
11. Li LY, Dai HY, Yeh FL, Kan SF, Lang J, Hsu JL, Jeng LB, Chen YH, Sher YP, Lin WC, Hung MC (2011) Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene 30:1773-1783
12. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, Han Z, Lin WC, Li LY, Hung MC (2009) Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 28:3286-3295
13. Sher YP, Liu SJ, Chang CM, Lien SP, Chen CH, Han Z, Li LY, Chen JS, Wu CW, Hung MC (2011) Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther 10:637-647
14. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
15. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC (2007) Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12:52-65 (Pubitemid 47001785)
16. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Spencer DM (2011) Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara(R) for prostate cancer therapy. J Gene Med 13:680-691
17. Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC (2012) Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther 11:1915-1924